SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Although the bivalent COVID-19 vaccine conferred moderate protection against symptomatic disease, hybrid immunity provided the strongest protection.

Scientists reveal that reactivation of Epstein-Barr virus (EBV), driven by TGFβ-induced immune suppression, is a key driver ...

The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

The following is a summary of “Association between SARS-CoV-2 and stroke: perspectives from a metaumbrella-review,” published ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...

PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1, XEC, and LP.8.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding ...

Several studies have suggested that COVID-19 may increase a person’s risk of developing cancer or promote metastasis of existing cancer.